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Objective. Weight gain is a side effect of glucocorticoid (GC) use, but the natural history and health implications of
changes in weight that occur during the treatment of inflammatory disease are not understood.
Methods. We evaluated data from the Wegener’s Granulomatosis Etanercept Trial. Patients were categorized according
to clinical outcome at 1 year: remission (no disease flares), single flare, or multiple flares. Risk factors for gaining >10 kg
were examined in multivariate models.
Results. Weights at baseline and 1 year were available for 157 (93%) of the 168 patients analyzed. During year 1, the mean
cumulative prednisone dosage in the multiple flares subgroup was 7.9 gm, compared with 6.0 gm and 3.9 gm in the single
flare and remission subgroups, respectively (P < 0.001). Patients in these subgroups gained an average of 2.6 kg, 4.1 kg,
and 5.8 kg, respectively (P  0.005). Weight gain did not correlate with cumulative GC dose (R  0.10, P  0.25).
Thirty-five patients (22.3%) gained and maintained >10 kg in the first year. New diagnosis of Wegener’s granulomatosis
at baseline was an independent predictor of gaining >10 kg at 1 year (odds ratio 19.7, 95% confidence interval 2.4–162.6,
P  0.006). Among the 78 patients in the remission subgroup, 40 sustained remissions through the 2-year time point. For
these 40 patients, the mean weight gained at year 1 did not regress by the end of year 2, despite the absence of continued
GC use.
Conclusion. Disease control was associated with lower cumulative GC doses but greater weight gain. More than one-fifth
of patients gained >10 kg in the first year of treatment. The quantity of weight gained by patients during treatment has
potential future health implications.
INTRODUCTION
Glucocorticoids (GCs) are integral to the treatment of in-
flammatory diseases, many of which are characterized by
recurrent disease flares that require repeated GC courses or
continuous use. Common conditions such as obstructive
and reactive airway diseases are frequently treated with
intermittent, short courses of GCs to maintain disease con-
trol (1,2). Other conditions such as inflammatory bowel
disease, systemic lupus erythematous, and systemic vas-
culitis require prolonged courses of GCs to induce remis-
sion or prevent relapses (3–6). In developed countries, the
prevalence of GC use is nearly 1% (7–9).
Despite their unquestionable benefits in many diseases,
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GCs also have numerous well-recognized side effects, in-
cluding weight gain. However, the natural history of
weight gain associated with GC use is not well understood.
To our knowledge, no study has investigated the amount,
duration, and course of weight change caused by GC use.
Wegener’s granulomatosis (WG), one of the most common
forms of systemic vasculitis, is the paradigm of diseases
associated with antineutrophil cytoplasmic antibodies.
GCs, combined with other immunosuppressive agents
such as cyclophosphamide or methotrexate, are the main-
stay of therapy for WG (6,10,11). The GC regimen used to
treat WG is typical of that used in the therapy of many
inflammatory conditions, i.e., high initial doses followed
by a tapering course over many months. For patients who
experience disease flares during or after the period of
remission induction, additional courses of GC are re-
quired. For some patients with persistently active disease,
maintenance therapy with the lowest effective dose of GC
is necessary.
In this study, we assessed the quantity, duration, and
progression of weight change in patients who received GCs
for active WG under a clinical trial protocol. Our study had
3 objectives. First, we tested the hypothesis that a stepwise
increase in weight gain across 3 study subgroups would be
observed. We anticipated that patients who achieved re-
mission and required no more prednisone after 6 months
(the remission subgroup) would gain less weight than
those who experienced single disease flares over the first
year of treatment (the single flare subgroup), who in turn
would gain less weight than those who experienced mul-
tiple disease flares over that period (the multiple flare
subgroup). Second, we hypothesized that patients who
achieved disease remission and maintained the remission
state would lose the weight gained during the period of GC
treatment. Finally, we performed a multivariate analysis to
determine risk factors for gaining and maintaining a min-
imum of 10 kg from baseline over the first year of treat-
ment.
PATIENTS AND METHODS
Data from the Wegener’s Granulomatosis Etanercept Trial
(WGET) formed the basis of this study (10). Members of the
WGET are listed in Appendix A. The WGET population
was well suited for studying the impact of GCs on weight
gain because of the tendency of many patients with WG to
experience disease flares and because of the requirement
for repeated GC courses to treat such flares. Moreover, data
from the WGET cohort included detailed evaluations of
disease status, e.g., disease activity (12), damage (13,14),
quality of life, and medication use at sequential time
points during the trial.
WGET design. The WGET was a randomized, double-
blind, placebo-controlled trial designed to test the efficacy
of etanercept (Enbrel; Amgen Corporation, Thousand
Oaks, CA), a soluble inhibitor of tumor necrosis factor, in
combination with conventional therapy for the mainte-
nance of remission (15). Details of the trial design, the
baseline evaluation of the cohort, and the overall trial
results have been published (10,15,16). The primary out-
come in the WGET was the ability of the experimental
medication to maintain disease remissions as conven-
tional immunosuppressive agents were tapered. A total of
180 patients with active WG either newly diagnosed or
recurrent at the time of trial entry (previously diagnosed)
were enrolled and followed for a median of 27 months.
Treatment regimen. Patients with severe WG, defined
as disease posing an immediate threat to the patient’s life
or the function of a vital organ (15), were treated with
cyclophosphamide and prednisone (0.5–1 mg/kg/day).
Methylprednisolone (1 gm/day for 3 days) could be admin-
istered at the investigator’s discretion at the start of ther-
apy. The initial prednisone regimen and its taper are
shown in Figure 1. Patients with limited WG at enroll-
ment, defined as disease that did not pose an immediate
threat to either life or vital organ function, were treated
with methotrexate and the same GC regimen as those with
severe disease, except that patients with limited disease
did not receive methylprednisolone pulses. Following 1
month of high-dose GC treatment, a taper was initiated
with the goal of discontinuing prednisone within 6
months of randomization.
Disease flare led to the resumption of systemic therapy
(15). Patients with severe flares were treated with regimens
of GCs and cyclophosphamide identical to those received
by patients who presented initially with severe disease.
Patients who experienced limited flares received increased
doses of GCs, methotrexate, or both. After 4 weeks at the
increased GC dose, the tapering regimen was resumed.
Baseline data collection. At enrollment, data on demo-
graphics, clinical characteristics, treatment history, and
selected medical history items were collected. Disease-
specific information (i.e., onset and diagnosis, specific or-
Figure 1. Prednisone tapering regimen. Patients with severe dis-
ease could receive intravenous methylprednisone (1 gm/day for 3
days) at the start of treatment.
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gan involvement, and disease flare history) was also col-
lected. The duration of use and maximum doses of all
medications used to treat WG were recorded.
Followup. Followup evaluations were scheduled at 6
weeks, 12 weeks, and every 3 months thereafter. At each
trial visit, interim medical events were captured on stan-
dardized followup history forms. At followup visits, pa-
tients’ weight, medications, and medication doses were
recorded. Patients were followed to a common closeout
date, designated to be 1 year after the last patient was
enrolled.
Body mass index. Patients’ height measured at baseline
and weight recorded at each trial visit were used to calcu-
late body mass index (BMI; kg/m2). We classified patients
at baseline into 1 of 6 National Heart, Lung, and Blood
Institute–defined categories for BMI (17): underweight
(BMI 18.5 kg/m2), normal weight (BMI 18.5–24.9 kg/m2),
overweight (BMI 25–29.9 kg/m2), obesity class I (BMI 30–
34.9 kg/m2), obesity class II (BMI 35–39.9 kg/m2), and
obesity class III (BMI 40 kg/m2).
Study subgroups. We defined 3 patient subgroups: re-
mission (patients who achieved disease control and ta-
pered off GC therapy without having to resume it during
the first year of therapy [n  78]), single flare (patients who
experienced 1 disease flare during the first year of treat-
ment [n  42]), and multiple flares (patients who experi-
enced more than 1 disease flare during the first year of
therapy [n  37]).
Statistical analysis. All GC doses administered during
the trial including methylprednisolone pulses were con-
verted to prednisone equivalents for the purposes of tab-
ulating cumulative doses. In initial analyses, univariate
differences between the study subgroups in categorical
variables were evaluated using either chi-square tests or
Fisher’s exact sign test. Continuous variables were evalu-
ated by the nonparametric Kruksal-Wallis test.
We selected 1 year, the minimum length of time in the
trial for any patient, as the point at which to evaluate our
primary weight change outcome. Because of the impor-
tance of longer-term followup studies in obesity, we also
evaluated time points beyond 1 year for patients for whom
such data were available. The change in absolute weight
from visit to visit was calculated by subtracting patients’
weight at every visit from the weight at baseline. The
significance of mean changes in weight was evaluated by
either the Mann-Whitney test (for comparisons of 2 sub-
groups) or the Kruksal-Wallis test (for comparisons of 3
subgroups).
Multiple logistic regression analysis was used to iden-
tify odds ratios for gaining and maintaining at least 10 kg
more than baseline weight during the first year of treat-
ment. The 10-kg weight gain is an arbitrary cutoff that most
patients can relate to and would deem significant. Vari-
ables examined in the multivariate analysis included base-
line weight; age; sex; smoking history; disease severity;
new diagnosis of WG at enrollment; treatment with etan-
ercept; hypertension; serum creatinine (1.4 mg/dl or
1.4 mg/dl); and baseline disease activity (12), damage
(13,14), and quality of life scores (18).
RESULTS
Baseline characteristics of patients as a function of
disease course. Among the 180 patients with WG origi-
nally enrolled in the trial, 6 died and 6 were lost to fol-
lowup during the first year. Thus, baseline and 1-year
followup data related to weight and BMI were available for
157 (93%) of the 168 patients. The baseline characteristics
of all 157 patients and the 3 subgroups are shown in
Table 1.
The mean  SD BMI at trial entry was 29  7 kg/m2.
Thirty-eight percent of all patients were obese (BMI 30
kg/m2) at baseline. There were significantly fewer patients
in the multiple flares group who had severe WG, and
significantly fewer who were newly diagnosed. In addi-
tion, patients in the multiple flares group had lower dis-
ease activity scores (Birmingham Vasculitis Activity Score
for WG) at baseline, but higher damage scores (Vasculitis
Damage Index).
Doses of GCs in the remission, single flare, and multiple
flare subgroups. The cumulative dose of GCs increased as
a function of the number of disease flares in the first year
(Figure 2). At the first followup visit (6 weeks), all 3 sub-
groups had received similar cumulative doses of GCs
(mean  SD prednisone dosage 1.92  1.00 gm). However,
at the 1-year interval, patients in the multiple flares sub-
group had received 7.90  3.50 gm of prednisone, com-
pared with 6.00  2.70 gm and 3.90  2.30 gm for patients
in the single flare and remission subgroups, respectively,
over the same period (P  0.001) (Figure 2).
Weight gain among all patients and the 3 subgroups.
The 3 subgroups had similar baseline weights (Table 1).
For the entire cohort, the mean  SD weight gain at 1 year
was approximately 3.9  6.9 kg, representing a 4.4% in-
crease from the mean baseline weight. Thirty-eight (24%)
of the 157 patients gained 10 kg over the first year of
treatment, with a mean increase in body weight of 11.2 kg
(13.5% over their mean baseline weight).
The weight gained by all patients and the 3 subgroups at
sequential time points is shown in Figure 3. Between the
3- and 6-month followup visits, patients in the multiple
flare, single flare, and remission subgroups reached
mean  SD maximum weight gains of 2.6  4.9 kg, 4.1 
4.4 kg, and 5.8  5.8 kg, respectively (P  0.011). The
mean percent gains in weight at 1 year by patients in the
multiple flares, single flare, and remission subgroups were
3.2%, 4.3%, and 5.1%, respectively. Weight gain did not
correlate with cumulative GC dose (R  0.10, P  0.25).
Weight gain in newly and previously diagnosed pa-
tients. The quantities of weight gained by patients who
were newly diagnosed with WG compared with those who
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were previously diagnosed at baseline are depicted in
Figure 4. Seventy (45%) of the 157 patients had new di-
agnoses of WG at baseline; 87 (55%) had undergone
courses of treatment for WG prior to the disease flare
leading to trial entry. The baseline weights were lower in
patients with new diagnoses of WG compared with pa-
tients who entered the trial with a previous diagnosis of
WG (mean  SD 82.8  21.6 kg versus 88.9  22.2 kg; P 
0.043). Although the peak weight gain occurred at 6
months for both groups, the newly diagnosed patients
gained 6.3  6.8 kg (7.3% increase from baseline weight)
over the first year, compared with only 1.9  6.4 kg (3.1%
increase from baseline weight) for the previously diag-
nosed patients (P  0.0001).









(n  37) P
Age, mean  SD years 49  15 51  16 48  12 45  15 0.13†
Male sex 58 63 57 49 0.35
White race 92 95 86 92 0.22
Height, mean  SD cm 173  11 173  10 173  11 171  12 0.37†
Weight, mean  SD kg 87  22 86  21 93  25 82  21 0.89†
BMI, mean  SD kg/m2 29  7 29  7 31  7 28  6 0.89†
BMI categories, kg/m2
Underweight (BMI 18.5) 1.9 3.8 0 0 0.23‡
Normal weight (BMI 18.5–
24.9)
26 31 12 32 0.05
Overweight (BMI 25–29.9) 34 33.3 43 27 0.32
Obese (BMI 30) 38.1 31.6 45 40.1 0.25
Newly diagnosed 45 56 45 19 0.014
Severe disease 68 74 71 51 0.041
Mean serum creatinine, mg/dl 1.5 1.7 1.5 1.2 0.33†
Serum creatinine 1.5 mg/dl 76 72 76 86 0.22
Never smoked 56 59 45 62 0.24
Menopause (% of women) 55 62 44 53 0.49
Hypertension 31 27 45 22 0.13
BVAS/WG, mean  SD 6.8  3.6 7.4  3.8 6.8  3.5 5.6  2.7 0.03†
VDI, mean  SD 1.3  1.7 1.0  1.6 1.4  1.7 2.0  1.8 0.004†
SF-36, mean  SD 49  28 46  28 57  29 45  26 0.10†
PCS 33  10 33  10 34  9 33  11 0.85†
MCS 44  12 44  12 46  12 42  11 0.18†
Etanercept group 49 50 55 41 0.44
* Values are the percentage unless otherwise indicated. BMI  body mass index; BVAS/WG  Birmingham Vasculitis Activity Score for Wegener’s
Granulomatosis; VDI  Vasculitis Damage Index; SF-36  Short Form 36; PCS  Physical Component Score; MCS  Mental Component Score.
† Kruksal-Wallis test.
‡ Fisher’s exact test.
Figure 2. Cumulative glucocorticoids used from baseline. At 6, 9, and 12 months, P values
were  0.001.
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Retention of weight at 2 years and beyond. Among
the 103 patients in the cohort with at least 2 years of
followup, the mean weight gain at 6 months was 4.2  7.2
kg. Forty patients achieved and maintained disease re-
missions through the 2-year visit. Among these 40 pa-
tients, the mean weight gained by 1 year was maintained
through the end of the second year (mean  SD weight
5.6  7.0 kg), despite the absence of additional GC use
after month 6. Among the 25 patients with followup at 2
years who had experienced multiple disease flares, the
mean weight gained at the 2-year time point was 1.03 
5.22 kg (P  0.014 compared with sustained remission
group).
Multivariate analysis. Results of the multivariate ana-
lysis are shown in Table 2. New diagnosis of WG at base-
line had the strongest association with a 10-kg weight gain
(odds ratio 19.7, 95% confidence interval 2.4–162.6, P 
0.006) and was the only significant risk factor for this
complication. Etanercept treatment was not associated
with weight gain, either in univariate or multivariate ana-
lyses (data not shown). Although male patients gained
more weight at 1 year than did female patients (mean  SD
4.9  6.6 kg versus 2.4  7.1 kg; P  0.02), sex was not
predictive of gaining and maintaining at least 10 kg more
than baseline weight.
DISCUSSION
Despite the role of GCs as the cornerstone of therapy for a
broad array of illnesses, to our knowledge this study is the
first to analyze the degree and duration of weight change
over the course of high-dose GC treatment for inflamma-
tory disease. Our findings indicate points of concern re-
lated to the quantities of weight gained by many patients
treated with GCs and the long-term health implications of
GC use. Twenty-two percent of the patients treated with
GCs in this study gained a minimum of 10 kg and main-
tained this weight at the time of their 1-year followup. In
these patients, the mean weight gained (11.2 kg) consti-
tuted a 13.5% increase over their baseline weight. Even
patients who required no additional GC courses for up to 2
years after entry failed to lose the weight they had gained
during the first 6 months of treatment.
We hypothesized that the patients who achieved and
maintained disease remissions would lose any weight
gained during the initial treatment of their disease flare
once they stopped taking GCs. In fact, patients tended to
retain the weight gained during GC treatment for the entire
duration of followup. The 40 patients who achieved and
maintained disease remissions over the first 2 years of
followup were actually heavier at year 2 than they were
upon completion of their GC taper (4.2 kg at month 6
Figure 3. Average weight gain of all patients and 3 study subgroups.
Figure 4. Average weight gain in patients with newly diagnosed versus previously diag-
nosed Wegener’s granulomatosis at baseline. P values at 3, 6, 9, and 12 months all  0.0001.
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versus 5.6 kg at year 2), despite the absence of any interim
GC therapy. Thus, patients who achieved and sustained
disease remission through year 2 were 12 pounds heavier
than when they entered the study. As noted, 38% of pa-
tients were already obese when they entered the study.
The tendency to maintain the weight gain during the treat-
ment of active inflammation is particularly concerning in
view of the proclivity of WG (and other inflammatory
illnesses) to recur and to require further GC treatment.
The results of this study suggest complex relationships
between disease control, cumulative GC dose, and weight
gain. We had hypothesized that more disease flares would
be associated with higher GC use and greater weight gain,
leading to a stepwise increase in weight gain across the 3
subgroups (multiple flares  single flare  remission).
Indeed, patients in the multiple flares subgroup received
32% more prednisone than those in the single flare sub-
group and 100% more than those in the remission sub-
group. Paradoxically, by the end of the first year, patients
in the multiple flares subgroup had gained the least
amount of weight among the 3 subgroups.
The relationships between GC use and weight gain ob-
served in this trial have several potential explanations.
First, weight loss caused by chronic inflammation has
been demonstrated in a number of disorders, including
cancer, rheumatoid arthritis, and the frailty syndrome (sar-
copenia) (19–28). The results of our study suggest that this
is also true in WG. Such an effect of inflammation on the
observed weight changes in this study is suggested by the
association of multiple disease flares with the least amount
of weight gain despite the highest cumulative doses of GC.
Second, the fact that previously diagnosed patients gained
less weight than newly diagnosed patients may be related
to behavioral modification: patients with previous diag-
noses of WG and familiarity with the effects of GCs may
have altered their dietary habits or increased their exercise
patterns to avoid excess weight gain from GC use. The fact
that a new diagnosis of WG emerged as the strongest pre-
dictor of large weight gain in our multivariate analysis
lends indirect support to this explanation. These data sug-
gest that providing patients with behavioral strategies per-
taining to exercise and diet might help diminish the im-
pact of GC treatment on their weight.
An alternative explanation for part of the weight change
observed in this study is that the weight gained was phys-
iologic: weight gained over the course of treatment may
represent a compensation for weight lost prior to the start
of therapy. However, dramatic weight loss occurs in only a
small minority of patients with WG (6,16). Moreover, the
baseline weights in our cohort did not suggest that a sub-
stantial proportion of our patients had cachexia. On the
contrary, 72% of the patients in our cohort were over-
weight or obese at trial entry, and only 2% were under-
weight at baseline (Table 1). Future studies that scrutinize
the pattern of weight change from premorbid weights fol-
lowing a period of active disease will help address this
question.
Weight gain, especially to the levels that constitute obe-
sity, is strongly linked to a variety of diseases with major
public health impact: type 2 diabetes, cardiovascular dis-
ease, knee osteoarthritis, sleep apnea, and many forms of
cancer (29). Obesity decreases lifespan (30), reduces qual-
ity of life (31), diminishes work productivity (32), and has
a substantial economic impact on society (33). Conse-
quently, GC-associated weight gain has implications for
the overall health of patients with inflammatory diseases,
especially in light of the maintenance of this weight gain
over time. The development of comorbidities prompted by
GC-associated weight gain could complicate patients’ fu-
ture clinical care.
This study has several important strengths as well as
potential weaknesses. First, although many complications
of GC therapy have been evaluated thoroughly (34,35), the
adverse effect of weight gain—the effect most obvious to
patients—has been relatively neglected. Thus, our study
opens a line of investigation into a neglected area not only
for WG, but for a host of conditions associated with in-
flammation. Second, the clinical trial setting in which
these data were collected permitted detailed analyses of
the degree, timing, and duration of weight gain in a pop-
ulation of patients treated with a standardized regimen of
GCs. The GC regimen used in this trial was comparable
with standard therapy for many serious inflammatory ill-
nesses. Therefore, it is likely that these data are relevant
for populations of patients with other inflammatory ill-
nesses whose treatment regimens are similar.
With regard to weaknesses, the number of patients stud-
ied in this investigation remains relatively small compared
with the size of other disease cohorts even though the
parent clinical trial is the largest prospective study of
patients with WG performed to date. Confirmation of these
findings in groups of patients with other systemic inflam-
matory illnesses will be important. Future analyses of such
patterns may yield knowledge related to clinical interven-
tions designed to mitigate GC-related weight gain.
Table 2. Multivariate model risk factors for predicting
10-kg weight gain*
Risk factors OR 95% CI P
Severe 1.6 0.3–7.7 0.54
Limited 1.0
New diagnosis 19.7 2.4–162.7 0.006
Previous diagnosis 1.0
Male 1.3 0.3–4.6 0.72
Female 1.0
No history of smoking 0.3 0.1–1.0 0.06
History of smoking 1.0
Placebo 0.99 0.3–3.4 0.98
Etanercept 1.0
Hypertension 1.0 0.3–3.9 0.99
No hypertension
Age 1.02 0.9–1.1 0.35
Baseline weight 0.99 0.9–1.0 0.45
Serum creatinine 1.4 0.8–2.4 0.22
BVAS/WG 0.917 0.8–1.1 0.35
VDI 0.84 0.5–1.3 0.47
SF-36
PCS 1.023 0.9–1.1 0.52
MCS 1.01 0.9–1.1 0.61
* OR  odds ratio; 95% CI  95% confidence interval; see Table 1
for additional definitions.
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In conclusion, we have quantified the degree and course
of weight gain over the course of treatment with high-dose
GCs. We observed a complex relationship between cumu-
lative GC dose and weight gain, and documented an in-
verse correlation between disease activity and weight gain:
patients with the best disease control had the lowest cu-
mulative GC doses, yet gained the most weight. New diag-
nosis at the time of trial entry was the strongest risk factor
for dramatic weight gain, suggesting that education at the
start of therapy about the effects of GC may be an impor-
tant prophylactic intervention. The retention of weight
gained during treatment may have significant future health
implications, even if the inflammatory disease remains in
remission and no further GC therapy is required.
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APPENDIX A: THE WEGENER’S
GRANULOMATOSIS ETANERCEPT TRIAL
RESEARCH GROUP
Members of the Wegener’s Granulomatosis Etanercept
Trial are as follows: John H. Stone (Chairman, The Johns
Hopkins Vasculitis Center); Gary S. Hoffman (Co-Chair-
man, Cleveland Clinic Foundation Center for Vasculitis
Research and Care); Janet T. Holbrook, Curtis L. Meinert,
John Dodge, Jessica Donithan, Nancy Min, Laurel Murrow,
Maria Oziemkowska, Jacki Smith, Andrea K. Tibbs, Mark
Van Natta (The Johns Hopkins University Center for Clin-
ical Trials); Robert Spiera, Iresha Abeynayake, Rosanne
Berman, Sandy Enuha (The Beth Israel Medical Center,
New York); Peter A. Merkel, Rondi Gelbard, Melynn Nuite,
Aileen Schiller (Boston University); David Blumenthal,
Debora Bork, Tiffany Clark, Sonya L. Crook, Leonard H.
Calabrese, Sharon Farkas, Sudhakar Sridharan, Kimberly
Strom, William Wilke (The Cleveland Clinic Foundation);
E. William St.Clair, Nancy B. Allen, Karen Rodin, Edna
Scarlett (Duke University); David B. Hellmann, Matthew
A. Marriott, Amanda M. Moore, Lourdes Pinachos, Mi-
chael J. Regan, Misty L. Uhlfelder (Johns Hopkins Uni-
versity); Ulrich Specks, Kristin Bradt, Kimberly Carlson,
Susan Fisher, Boleyn Hammel, Kathy Mieras, Steven
Ytterberg (The Mayo Clinic); John C. Davis, Anne Marie
Duhme, Maureen Fitzpatrick, Ken Fye, Steve Lund (Uni-
versity of California, San Francisco); Joseph McCune,
Billie Jo Coomer, Barbara Gilson, Hilary Haftel, Ana
Morrel-Samuels, Sandra Neckel (University of Michigan);
Noel R. Rose, C. Lynne Burek, Jobert Barin, Monica Talor
(The Johns Hopkins University Immune Diseases Labora-
tory); Paul L. Canner (Maryland Medical Research Insti-
tute); Doyt L. Conn (Emory University); John H. Klippel
(Arthritis Foundation); J. Richard Landis (University of
Pennsylvania).
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